Posted by Michael Wonder on 24 Jul 2023
Overland ADCT BioPharma announces NMPA accepts biologics license application and grants priority review for Zylonta for treatment of relapsed or refractory diffuse large B-cell lymphoma
24 July 2023 - Overland ADCT BioPharma today announced that the China NMPA has accepted the Biologics License Application for Zylonta (loncastuximab tesirine-lpyl), which is seeking an indication for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in China.
The BLA has been granted priority review by the NMPA.
